Shares of CTI tumble 25% |
Connect with TechFlash on our Facebook page for all the latest technology news headlines and commentary, plus information and access to special events, photos from events, promotions and more.
Today On Techflash
- Can Microsoft overcome the smartphone app gap?
- Hey recruiters: Here's an R&D lab run by, and for, students
- Apps that waste your time (in a good way): Execs' addictions
- WTIA announces Industry Achievement Award finalists
- Analyst sees 7-inch iPad in Apple future
- Check out this app: Executives list the ones they use most
Mass High Tech
- Microsoft Build: Windows 8 preview a hit, but are investors unhappy?
- Build an app in a day at Mobile App Hackathon
- Beefed-up Skype for Windows; Indie author joins Amazon's 'Kindle Million Club'
- Only solution to Xbox 360 update error is new console
- Ballmer: Windows Phone update 'Mango' has over 500 new features
Jeff Bezos Watch
- Jeff Bezos 'grateful' to be selling millions and millions of Kindles
- Nick Hanauer and others invest $3.1 million in Qliance
- Survey: Employees say it's just 'OK' to work at Microsoft
- Jeff and MacKenzie Bezos give $15M for Princeton brain center
- Newsmaker of the Year surprise: Savitt beats Bezos, Allen
Shares of CTI tumble 25%
Cell Therapeutics Inc. lost more than 25 percent of it value this morning after the U.S. Food and Drug Administration questioned whether the Seattle biotech enrolled enough patients to test its experimental drug fro non-Hodgkin's lymphoma. The FDA report also questioned the toxicity of the drug, known as pixantrone. The stock was trading at 79 cents, down about 26 cents on the day. Shares fell to as low as 60 cents at one point this morning.
The FDA report said that CTI had planned to enroll 320 patients at 189 sites. But the company only attracted 140 patients at 66 sites for the study.
"The applicant stated that enrollment was hampered by investigator reluctance to enroll patients and that many investigators preferred to use either multi-agent chemotherapy or supportive care in this 3rd line population," the FDA report said.
The FDA is scheduled to meet on Wednesday to decide if the non-Hodgkin's lymphoma drug, pixantrone, should receive approval.
Xconomy has more details on the report, noting that the FDA still has questions about the quality of data in the study as well as the risk-reward qualities of the drug.
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
TechFlash Team
Recent Sponsor Posts
Who's creating today's energy efficient buildings? Find out at the BetterBricks Awards, Feb. 16
BetterBricks Awards salute the individuals leading the way for high performance commercial buildings with an emphasis on energy efficiency. Join us as we recognize these standout green building professionals.
Award categories include: Advocate; Architect/Designer; Facility Manager/Operator; and Owner/Developer.
Keynote Speaker: Kevin Kampschroer, Director of U.S. GSA's Office of Federal High Performance Buildings. Kevin leads the U.S. General Services Administration's efforts in building sustainability and accelerating industry adoption of sustainable principles across all aspects of a building's life.
Register here by February 10!
If you are interested in buying a table, email Monica Alquist or call her at 206-876-5404.
The Triple Door Presents: The Atomic Bombshells "J'ADORE!: A Burlesque Valentine"
Seattle's reigning Burlesque super-troupe delivers a gorgeous and glittering VALENTINE featuring some of the Bombshells' most exhilarating acts to date. J'Adore! promises to celebrate l'amour with good humor, style, and a healthy dose of dazzle! Bring a friend, a lover, a family member, or a secret crush, and celebrate with the Valentine's Burlesque spectacular that will leave you shouting: "J'ADORE......The Atomic Bombshells!" The incomparable Jasper McCann emcees with high style and charm.
Please visit www.thetripledoor.net for a full schedule of future performances.
The Triple Door Presents: Bob Mould – See A Little Light: An Evening of Reading and Music
"Bob Mould. Those two words are synonymous with integrity. From Husker Du in the last century to right at this moment, Bob is the real deal, writing and playing music for music's sake. He's a great songwriter and performer. I have been a fan of Bob's for thirty years now with no end in sight." -Henry Rollins
Please visit www.thetripledoor.net for a full schedule of future performances.
Why Choose BDO for your SOC (previously SAS 70) Reports?
BDO’s experience in providing attestation services (SAS 70/SSAE 16, AT 101, AT 201, AT 601, etc.) to a broad range of industries, and our team of skilled professionals distinctly qualifies us to serve as your company’s Service Auditor. By leveraging the BDO global network of control specialists, we are poised to provide global services in more than 1,000 offices and across 119 countries. Many organizations find that investing in reports on controls may result in benefits, including:
• Increased client confidence
• Improved competitive advantage
• Minimization of frequent audits
• Streamlined business processes and controls
• Enhanced risk management
For detailed information contact Paul Martini at pmartini@bdo.com.
TechFlash Archive
- February 2012 (52)
- December 2011 (203)
- October 2011 (256)
- August 2011 (257)
- June 2011 (191)
- April 2011 (195)
- February 2011 (153)
- December 2010 (142)
- October 2010 (248)
- August 2010 (208)
- January 2012 (196)
- November 2011 (258)
- September 2011 (286)
- July 2011 (201)
- May 2011 (194)
- March 2011 (208)
- January 2011 (158)
- November 2010 (231)
- September 2010 (240)
- July 2010 (204)
